PDF factsheet

antithrombotics in superficial thrombophlebitis for superficial thrombophlebitis of the leg , clinical trials results

complete stripping versus low dose heparin
Belcaro (complete stripping vs low dose hep), 1999	surgery (complete stripping) versus low-dose subcutaneous heparinitm
coumadin versus low dose heparin
Belcaro (coumadin vs low dose hep), 1999	coumadin versus low-dose subcutaneous heparin
defibrotide versus low dose heparin
Belcaro, 1990	Defibrotide versus low-dose heparin	with ST
desmin 200 versus desmin 100
Andreozzi (200 vs 100), 1996	Dermatan sulfate (Desmin) (100 mg twice s.c.)y8 versus Desmin (100 mg once daily s.c.)	Patients with ST or varicophlebitis of the lower limbs
desmin SC versus desmin 100
Andreozzi (desmin SC vs 100), 1996	versus
Diclofenac versus placebo
Nocker (diclofenac), 1991	Diclofenac gel (1 g diclofenac/100 g gel) for 3 weeks versus placebo	patients with unilateral thrombophlebitis of the legs
enoxaparin versus placebo
STENOX (enoxaparin 1.5mg/hg), 2003	enoxaparin (s.c. 1.5 mg/kg)for 8-12 days versus placebo	patients with St of at least 5 cm on ultrasonography examination
Stenox (enoxaparin 40mg), 2003	LMWH (enoxaparin) (s.c. 40 mg) for 8-12 days versus placebo.	patients with ST of at least 5 cm on ultrasonography examination
Essaven versus placebo
De Sanctis, 2001	Essaven gel (5 cm of gel) for 4 weeks versus placebo	patients with superficial thrombophlebitis and varicose veins
Incandela, 2001	Essaven gel (5 cm of gel) versus placebo	patients with ST associated with varicesm
Etofenak versus diclofenac
Holzgreve, 1989	Etofenak gel versus diclofenac gel	patienst with superficial venous thrombosis
Exhirud ointment versus placebo
Nocker (exhirud), 1991	versus
Fixed-dose LMWH versus NSAIDs
STENOX (enox fixed dose vs NSAIDS), 2003	versus
fondaparinux versus placebo
CALISTO, 2010 NCT00443053	fondaparinux 2.5mg up to 45 days versus placebo	patients with acute symptomatic isolated superficial thrombophlebitis of the lower limbs	double blind Follow-up duration: 45 days (77d) 17 countries
Heparansulphate versus sulodexide
Messa, 1997	Heparansulphate (100 mg 3 times daily orally) for 2 weeks versus sulodexide (250 LSU twice daily, orally)	patients with ST
heparin versus low dose UFH
Marchiori, 2002	UFH (s.c. 12500 IU for one week then 10000 IU) for 4 weeks versus UFH (5000 IU)	patients with ST of the great saphenous vein
heparin versus no treatment
Belcaro (hep vs no hep), 1989	versus
heparin spraygel versus clexane
Gorski, 2005	Topical liposomal heparin spraygel (4 puffs of 458 IU three times daily) versus clexane (40 mg once daily)	patients with symptomatic superficial venous thrombosis confirmed by ultrasonography with first symptoms not earlier than 72 hours
Indomethacin versus placebo
Anonymous, 1970	Indomethacin 50mg 3 times daily for 1 week versus placebo	patients with superficial thrombophlebitis of calf and/or thigh	double blind
ligation versus low dose heparin
Belcaro (ligation vs low dose hep), 1999	ligation versus low-dose subcutaneous heparin
liposomal heparin-spraygel versus enoxaparin
Katzenschlager, 2003	Topical liposomal heparin-spraygel (lipohep 2400 IU/g, 4 spray puffs three times daily) for 7-14 days versus enoxaparin (40 mg s.c.) for 7-14 days	with ST diagosed by ultrasound with signs and symptoms lasting less than 72 hoursdaily)o
LMWH versus heparin spraygel
Gorski (LMWH vs hep spraygel), 2005	versus
Katzenschlager (LMWH vs hep spraygel), 2003	versus
LMWH versus low dose heparin
Belcaro (LMWH vs low dose hep), 1999	LMWH versus low-dose subcutaneous heparinitm	Patients with ST and large varicose veins
nadroparin versus naproxene
Titon (nadroparin 0.6ml vs naproxen), 1994	nadroparin (s.c. 0.6 ml for 6150 IU anti-Xa once daily)j versus Naproxene (oral 500 mg once daily)	patients with ST
Titon (nadroparin 61.5 IU anti-Xa/kg vs naproxen), 1994	nadroparin (s.c. 0.6 ml for 6150 IU anti-Xa once daily)j versus Naproxene (oral 500 mg once daily)	patients with ST
nadroparin fixed-dose versus nadroparin weight-adjusted
Vesalio, 2005	LMWH (nadroparin) body-weight adjusted (full dose for 10 days followed by half dose for 20 additional days)àÄ† versus nadroparin (2850 anti-Xa IU) for 30 days	patients with superficial vein thrombosis of the great saphenous vein with the thrombosis extending up to 3 cm from the sapheno-femoral junction
Nimesulide versus diclofenac
Ferrari, 1992	Nimesulide 100 mg twice dailyitm versus diclofenac sodium 50 mg twice daily for 10 days	with acute ST
Oral acetamin versus diclofenac
Nusser, 1991	Oral acetamin (60 mg three times daily) for 15 weeks versus diclofenac (50 mg three times daily)	patients with ST
Oxyphenbutazone versus placebo
Archer, 1977	Oxyphenbutazone 100 mg 4 times daily for 7 days versus placebo	patients with superficial thromboplebitis	open
Prophylactic LMWH versus NSAIDs
STENOX (prophylactic LMWH vs NSAIDs), 2003	versus
Prophylactic UFH versus no treatment
Belcaro (prophylactic UFH vs no), 1999	versus
tenoxicam versus placebo
STENOX (tenoxicam vs PBO), 2003	oral tenoxicam (20 mg) for 8-12 days versus placebo
Therapeutic LMWH versus saphenofemoral disconnection
Lozano, 2003	Enoxaparin 1mg/kg twice daily for the first week, then 1mg/kg for 3 weeks versus saphenofemoral disconnection	patients with saphenous proximal thrombophlebitis
thrombectomy plus ECB versus ECB
Belcaro, 1989	Superficial thrombectomy plus ECBp, imag versus ECB alone	Patients with ST without DVT
Topical methylthioadenosine versus placebo
Pinto, 1992	Topical 5’-methylthioadenosine 0.5% (0.1 ml/cm skin 3 times/day) for 1 week versus placebo	patients with superficial phlebitis
Vasotonin forte versus placebo
Kuhlwein, 1985	Vasotonin forte for 3 weeks versus placebo	patients with ST
Wobenzym versus placebo
Koshkin, 2001	Systemic enzyme therapy (Wobenzym) (10 tablets 3 times daily) for 16 days versus placebo	with acute ST
Marshall, 2001	Wobenzym (4 tablets 3 times daily)for 12-16 days versus placebo	with acute ST of the leg

Options

Group by
in first

in second

Order trials by

Filter

display ongoing trials

Type of trial

Limit to tags

Exclude tags